---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132301"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:13:04.409603+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M

## Summary
- Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.
- Stockholders approved increase in authorized common shares from 250M to 350M, effective May 29, 2025.
- Second amendment to 2022 stock plan approved, adding 7M shares to the reserve.
- Dr. Shefali Agarwal and Dr. Bahram Valamehr re-elected Class III directors; E&Y ratified as auditor.
- Non-binding say-on-pay passed with ~68.9M for (92.4% of votes cast); frequency set at 1 year.

## SEC filing metadata
- accession: 0001193125-25-132301
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132301
- JSON: https://secwatch.observer/filing/0001193125-25-132301.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132301.txt

## Key facts
- Executive change
  Timothy P. Coughlin departed as Director at FATE THERAPEUTICS INC.
  - Action: term ended
  - Role: Director
  source text: Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm
- Executive change
  Matthew Abernethy was appointed as Class III Director at FATE THERAPEUTICS INC.
  - Action: appointed
  - Role: Class III Director
  source text: appointed Matthew Abernethy to the Board to serve as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm
- Governance Changes
  FATE THERAPEUTICS INC: Increased authorized shares of Common Stock from 250,000,000 to 350,000,000 (effective 2025-05-29).
  - Change: charter amendment
  - Effective: 2025-05-29
  source text: to increase the number of authorized shares of Common Stock from 250,000,000 shares to 350,000,000 shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.